Beyond Herceptin and Gleevec

Current Opinion in Chemical Biology

Volumn 7, Issue 4, 2003, Pages 490-495

  Fischer, Oliver M ^a   Streit, Sylvia ^a   Hart, Stefan ^a   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 C 4; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANERTINIB; CETUXIMAB; CGP 69846A; CISPLATIN; CP 724714; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; ISIS 3521; L 779 450; LAPATINIB; MATUZUMAB; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; ONCOPROTEIN; OSIDEM; PELITINIB; R 3; RUBOXISTAURIN; SEMAXANIB; SUNITINIB; TAK 165; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL STROMAL TUMOR; GENE THERAPY; HUMAN; MOLECULE; ONCOGENE NEU; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR CELL;

EID: 0042071479     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(03)00082-6     Document Type: Review

References (47)

1. Downward J., Yarden Y., Mayes E., Scrace G., Totty N., Stockwell P., Ullrich A., Schlessinger J., Waterfield M.D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307:1984;521-527.
2. Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Lee J., Yarden Y., Libermann T.A., Schlessinger J.et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:1984;418-425.
3. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410:1997;83-86.
4. Riese D.J. II, Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 20:1998;41-48.
5. Prenzel N., Fischer O.M., Streit S., Hart S., Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 8:2001;11-31.
6. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:1987;177-182.
7. Chazin V.R., Kaleko M., Miller A.D., Slamon D.J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene. 7:1992;1859-1866.
8. Kumar R., Shepard H.M., Mendelsohn J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol. 11:1991;979-986.
9. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:1992;4285-4289.
10. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., Figari I., Kotts C.E., Palladino M.A. Jr., Ullrich A.et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol. 11:1991;117-127.
11. Lane H.A., Beuvink I., Motoyama A.B., Daly J.M., Neve R.M., Hynes N.E. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol. 20:2000;3210-3223.
12. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61:2001;4744-4749.
13. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G.et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17:1999;2639-2648.
14. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M.et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:2002;719-726.
15. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M.et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:2001;783-792 This paper describes the results of a phase III study of Trastuzumab combined with chemotherapy compared to chemotherapy alone in patients with metastatic breast cancer. Combination of Trastuzumab and chemotherapy resulted in longer treatment response and improved survival, demonstrating the benefit of targeting an RTK with an antibody.
16. Hudziak R.M., Lewis G.D., Winget M., Fendly B.M., Shepard H.M., Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 9:1989;1165-1172.
17. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur J Cancer. 37(Suppl 4):2001;S9-15.
18. Kawamoto T., Sato J.D., Le A., Polikoff J., Sato G.H., Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA. 80:1983;1337-1341.
19. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 8:2001;3-9.
20. Kris M.G., Baööa B. A phase II trial of ZD1839 ('Iressa') in advanced non-small lung cancer (NSCLC) patients who failed platinum and doctazel-base regimens (IEAL20). Proc Am Soc Clin Oncol. 21:2002;292a.
21. Fukuoka M., lklbbhlk A. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol. 21:2002;298a.
22. Johnson DH, Herbst R: ZD1839 ('Iressa') in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002, 13(Suppl.5).
23. Giaccone G., Johnson D.H., Manegold C. An phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol. 2002:2002;40a.
24. Homepage of the American Society of Clinical Oncology on World Wide Web URL: http://www.asco.org .
25. Norman P. OSI-774 OSI Pharmaceuticals. Curr Opin Investig Drugs. 2:2001;298-304.
26. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A.et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 291:1999;739-748.
27. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2:2002;727-739.
28. Millauer B., Longhi M.P., Plate K.H., Shawver L.K., Risau W., Ullrich A., Strawn L.M. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620.
29. Giles F.J., Cooper M.A., Silverman L., Karp J.E., Lancet J.E., Zangari M., Shami P.J., Khan K.D., Hannah A.L., Cherrington J.M.et al. Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases. Cancer. 97:2003;1920-1928.
30. Fiedler W.M., Tinnefeld H., Mende T.et al. A Phase II study with SU5416 in patients with c-kit positive AML. Proc Am Soc Clin Oncol. 20:2001;288a.
31. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T.et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60:2000;2178-2189.
32. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B.et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 9:2003;327-337.
33. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol. 28:2001;27-33.
34. Ostman A., Heldin C.H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res. 80:2001;1-38.
35. van der Voort R., Taher T.E., Derksen P.W., Spaargaren M., van der Neut R., Pals S.T. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res. 79:2000;39-90.
36. Longati P., Comoglio P.M., Bardelli A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr Drug Targets. 2:2001;41-55.
37. Huang S., Houghton P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 3:2002;295-304.
38. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA. 98:2001;10314-10319.
39. Podsypanina K., Lee R.T., Politis C., Hennessy I., Crane A., Puc J., Neshat M., Wang H., Yang L., Gibbons J.et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA. 98:2001;10320-10325.
40. Kim K.S., Sack J.S., Tokarski J.S., Qian L., Chao S.T., Leith L., Kelly Y.F., Misra R.N., Hunt J.T., Kimball S.D.et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J Med Chem. 43:2000;4126-4134.
41. Motwani M., Delohery T.M., Schwartz G.K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 5:1999;1876-1883.
42. Magee T., Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell. 98:1999;9-12.
43. Dancey J.E. Agents targeting ras signaling pathway. Curr Pharm Des. 8:2002;2259-2267.
44. Betensky R.A., Louis D.N., Cairncross J.G. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol. 20:2002;2495-2499 This paper highlights the problem of molecular heterogeneity within patient populations and the possible consequences for the outcome of clinical investigations when this molecular heterogeneity is not recognized.
45. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 344:2001;1038-1042 The authors show that treatment of patients suffering from chronic myeloid leukemia in the blast crisis with Gleevec results in response rates from 60-70%, but two third relapse within 3-6 months. Together with [33] this paper demonstrates that additional molecular abnormalities can impair the effect of a drug.
46. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880 This paper shows that resistance to Gleevec can arise from additional molecular abnormalities. Investigating patients that relapsed after treatment with Gleevec the authors identified gene amplification of BCR-Abl and point mutations in the kinase domain as the molecular causes for drug resistance.
47. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T.et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536 The authors present a gene expression profiling approach to classify breast tumours and to predict their clinical outcome, as histological investigations and lymph node status fail to accurately classify these malignancies according to their clinical behaviour.